NYSE Content Update: Alto Neuroscience Raises $120 Million to Fund Development of ALTO-207

Rhea-AI Summary

Alto Neuroscience will discuss a $120 million private placement to advance development of its psychiatric candidate ALTO-207 on NYSE Live on March 23, 2026. Nick Smith, Alto CFO, will appear on NYSE Live to explain the financing and its intended use.

The NYSE pre-market update for March 23, 2026 also covers market movement after postponed strikes on Iran, an AI-at-work KPMG survey, RSAC conference coverage, and corporate notes including Copa Airlines (NYSE: CPA) and Jacobs (NYSE: J).

Positive

• $120 million private placement to fund ALTO-207 development
• CFO media appearance on NYSE Live increases investor visibility

Negative

• None.

News Market Reaction – CPA

+4.04%

4 alerts

+4.04% Session close to close

+14.5% Peak Tracked

$4.70B Market Cap

0.1x Rel. Volume

In the Mar 23 session, CPA gained 4.04%, reflecting a moderate positive market reaction. Argus tracked a peak move of +14.5% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement centers on NYSE programming, highlighting Alto Neuroscience’s $120 million private...

Analysis

This announcement centers on NYSE programming, highlighting Alto Neuroscience’s $120 million private placement and ceremonial events such as Copa Airlines’ 20th listing anniversary and a Jacobs leadership gathering of 180 executives. For Copa, the mention is visibility‑oriented rather than fundamentally focused. Investors monitoring this name may instead look to future traffic updates, earnings quality, and regulatory filings as more material drivers of performance.

Key Figures

Private placement size: $120 million Listing anniversary: 20th Leadership attendees: 180 leaders

3 metrics

Private placement size $120 million Alto Neuroscience financing to fund ALTO-207 development

Listing anniversary 20th Copa Airlines NYSE listing anniversary celebrated at Opening Bell

Leadership attendees 180 leaders Jacobs’ global executive leadership team meeting in Midtown

Historical Context

5 past events · Latest: Mar 16 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 16	Traffic statistics	Positive	+2.3%	February 2026 traffic showed double‑digit ASM and RPM growth with higher load factor.
Feb 26	Annual report filing	Neutral	-6.4%	Form 20‑F filing provided audited 2025 financials and access to detailed disclosures.
Feb 11	Earnings results	Positive	-0.1%	Reported strong 4Q25 and 2025 net profit with solid margins and a US$1.71 dividend.
Feb 09	Traffic statistics	Positive	-0.1%	January 2026 metrics showed ASM and RPM growth with higher system load factor.
Jan 13	Traffic statistics	Positive	-4.2%	December 2025 traffic data indicated continued demand recovery and improved seat utilization.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Operational updates with traffic growth often saw mixed or negative next-day moves, while strong earnings in Feb 2026 drew a flat-to-slightly-negative reaction despite robust profitability.

Recent Company History

This announcement comes after a series of operational and regulatory updates for Copa Holdings. Recent monthly traffic releases for December 2025, January 2026, and February 2026 all showed double‑digit ASM and RPM growth with improving load factors, yet price reactions ranged from modest gains to notable declines. The Feb 11, 2026 earnings report highlighted a full‑year 2025 net profit of US$671.6 million and a quarterly dividend of US$1.71 per share. A Form 20‑F filing on Feb 26, 2026 coincided with a sharper negative move.

Key Terms

private placement

1 terms

private placement financial

"company's $120 million in private placement financing to help advance its mission"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NYSE issues a pre-market daily advisory direct from the trading floor.

NEW YORK, March 23, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. 

Ashley Mastronardi delivers the pre-market update on March 23^rd

• Stocks jump and oil retreats after President Donald Trump postpones strikes on Iran energy targets with ceasefire talks beginning.
• Alto Neuroscience CFO Nick Smith will join NYSE Live to discuss the company's $120 million in private placement financing to help advance its mission of matching patients with the right psychiatric medications.
• An executive from KPMG will join NYSE Live to share the results of a new survey that looks at how employees are using AI in the workplace.
• The RSAC Conference, focusing on cybersecurity innovation and AI-driven defense, kicks off today from San Francisco.

For market insights, IPO activity, and today's opening bell, download the NYSE TV app at tv.nyse.com

Opening Bell
Copa Airlines (NYSE: CPA) celebrates 20^th listing anniversary.

Closing Bell
Jacobs (NYSE: J) hosts global executive leadership team meeting for 180 leaders in Midtown and visiting the NYSE.

Click here to download the NYSE TV App

View original content to download multimedia:https://www.prnewswire.com/news-releases/nyse-content-update-alto-neuroscience-raises-120-million-to-fund-development-of-alto-207-302722038.html

SOURCE New York Stock Exchange

FAQ

What did Alto Neuroscience announce about the $120 million financing on March 23, 2026?

Alto Neuroscience announced a $120 million private placement to advance ALTO-207 development. According to Alto Neuroscience, the financing is intended to help match patients with appropriate psychiatric medications and support clinical development activities.

When will Alto Neuroscience CFO Nick Smith appear on NYSE Live to discuss the financing?

Nick Smith will join NYSE Live on March 23, 2026 to discuss the private placement. According to Alto Neuroscience, the appearance will cover the use of proceeds and how financing supports ALTO-207 development plans.

How does the $120 million private placement affect Alto Neuroscience's development of ALTO-207?

The financing is intended to fund advancement of ALTO-207 in psychiatric drug development. According to Alto Neuroscience, proceeds will be used to accelerate clinical and development activities tied to matching patients to medications.

Where can investors watch the Alto Neuroscience discussion on NYSE Live on March 23, 2026?

Investors can view the segment on NYSE Live / NYSE TV on March 23, 2026. According to NYSE, the pre-market update and live interviews are available via the NYSE TV app and website.

Did the March 23, 2026 NYSE pre-market update include other market news affecting NYSE: J?

Yes, the pre-market update covered wider market moves and corporate notes including Jacobs (NYSE: J) hosting a global leadership meeting. According to NYSE, the update also mentioned market reactions and conference coverage.

What investor information did the NYSE pre-market update provide on March 23, 2026?

The NYSE pre-market update provided market context, corporate appearances, and event coverage for March 23, 2026. According to NYSE, it included trading-floor insights, company interviews, IPO activity, and opening bell information.